Heppner Jonathan M, Zaucke Frank, Clarke Lorne A
Department of Medical Genetics, University of British Columbia, 950 West 28 Avenue, Vancouver, British Columbia V5Z-4H4, Canada; The Child and Family Research Institute, University of British Columbia, 950 West 28 Avenue, Vancouver, British Columbia V5Z-4H4, Canada.
Center for Biochemistry, Medical Faculty, University of Cologne, Cologne, Germany; Cologne Center for Musculoskeletal Biomechanics, Medical Faculty, University of Cologne, Cologne, Germany.
Mol Genet Metab. 2015 Feb;114(2):146-55. doi: 10.1016/j.ymgme.2014.09.012. Epub 2014 Oct 7.
Progressive skeletal and connective tissue disease represents a significant clinical burden in all of the mucopolysaccharidoses. Despite the introduction of enzyme replacement strategies for many of the mucopolysaccharidoses, symptomatology related to bone and joint disease appears to be recalcitrant to current therapies. In order to address these unmet medical needs a clearer understanding of skeletal and connective tissue disease pathogenesis is required. Historically the pathogenesis of the mucopolysaccharidoses has been assumed to directly relate to progressive storage of glycosaminoglycans. It is now apparent for many lysosomal storage disorders that more complex pathogenic mechanisms underlie patients' clinical symptoms. We have used proteomic and genome wide expression studies in the murine mucopolysaccharidosis I model to identify early pathogenic events occurring in micro-dissected growth plate tissue. Studies were conducted using 3 and 5-week-old mice thus representing a time at which no obvious morphological changes of bone or joints have taken place. An unbiased iTRAQ differential proteomic approach was used to identify candidates followed by validation with multiple reaction monitoring mass spectrometry and immunohistochemistry. These studies reveal significant decreases in six key structural and signaling extracellular matrix proteins; biglycan, fibromodulin, PRELP, type I collagen, lactotransferrin, and SERPINF1. Genome-wide expression studies in embryonic day 13.5 limb cartilage and 5 week growth plate cartilage followed by specific gene candidate qPCR studies in the 5week growth plate identified fourteen significantly deregulated mRNAs (Adamts12, Aspn, Chad, Col2a1, Col9a1, Hapln4, Lum, Matn1, Mmp3, Ogn, Omd, P4ha2, Prelp, and Rab32). The involvement of biglycan, PRELP and fibromodulin; all members of the small leucine repeat proteoglycan family is intriguing, as this protein family is implicated in the pathogenesis of late onset osteoarthritis. Taken as a whole, our data indicates that alteration of the extracellular matrix represents a very early event in the pathogenesis of the mucopolysaccharidoses and implies that biomechanical failure of chondro-osseous tissue may underlie progressive bone and joint disease symptoms. These findings have important therapeutic implications.
进行性骨骼和结缔组织疾病是所有黏多糖贮积症中的一项重大临床负担。尽管针对许多黏多糖贮积症已采用了酶替代疗法,但与骨和关节疾病相关的症状似乎对当前治疗具有顽固性。为了满足这些未得到满足的医疗需求,需要更清楚地了解骨骼和结缔组织疾病的发病机制。从历史上看,黏多糖贮积症的发病机制一直被认为与糖胺聚糖的进行性蓄积直接相关。现在对于许多溶酶体贮积症而言,很明显更复杂的致病机制是患者临床症状的基础。我们在小鼠黏多糖贮积症I模型中使用蛋白质组学和全基因组表达研究来鉴定在显微切割的生长板组织中发生的早期致病事件。研究使用3周龄和5周龄的小鼠进行,因此代表了骨骼或关节未发生明显形态学变化的时期。采用无偏倚的iTRAQ差异蛋白质组学方法来鉴定候选物,随后通过多反应监测质谱和免疫组织化学进行验证。这些研究揭示了六种关键的结构和信号细胞外基质蛋白的显著减少;双糖链蛋白聚糖、纤维调节素、富含脯氨酸的细胞外基质蛋白、I型胶原、乳铁传递蛋白和丝氨酸蛋白酶抑制剂F1。对胚胎第13.5天肢体软骨和5周龄生长板软骨进行全基因组表达研究,随后在5周龄生长板中对特定基因候选物进行定量PCR研究,确定了14种显著失调的mRNA(含金属蛋白酶和凝血酶12、天冬氨酸蛋白、软骨黏蛋白、II型胶原α1链、IX型胶原α1链、透明质酸结合蛋白4、层黏连蛋白、基质金属蛋白酶诱导因子1、基质金属蛋白酶3、骨生成素、骨膜蛋白、脯氨酰4-羟化酶2、富含脯氨酸的细胞外基质蛋白和Rab32)。双糖链蛋白聚糖、富含脯氨酸的细胞外基质蛋白和纤维调节素的参与;小富含亮氨酸重复蛋白聚糖家族的所有成员都很有趣,因为这个蛋白质家族与迟发性骨关节炎的发病机制有关。总体而言,我们的数据表明细胞外基质的改变是黏多糖贮积症发病机制中的一个非常早期的事件,这意味着软骨-骨组织的生物力学功能障碍可能是进行性骨和关节疾病症状的基础。这些发现具有重要的治疗意义。